A comprehensive 2026 guide to UK online casinos with a 400% bonus. Understand wagering, find the best offers, and see if a 4x match is actually worth it. Read our full guide to 400% casino bonuses
OrbusNeich Announces Enrollment of First Patient in Japan Clinical Trial for its Proprietary Drug-Coated Balloon
OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty…
OrbusNeich Achieves Record-breaking Revenue, Sales Volume and Gross Profit in FY2025, Net Profit Rises to US$42 million, Final Dividend Increases by 20% to HK12 Cents per Share
– Sharpens Competitive Edge in Commercialization and Product Innovation – While Exploring New Business Models for Sustainable Growth Results Highlights: Revenue increased by 10.0% year-on-year to a record high of…
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively
– Declares Special Dividend of HK15 Cents per Share to Celebrate 25th Anniversary – Leveraging Strategic Global Footprint and Innovative Products to Navigate Macroeconomic Challenges and Capture Strong Market Demand…
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million
– Proposes a Final Dividend of HK10 Cents per Share – Strengthens Foundation via Continuous Innovation, Global Sales Network, Enriched Product Lines and Consolidation of New Acquisitions to Seize opportunities…
OrbusNeich Records Net Profit of US$18.8 Million for the First Half of 2024
– Robust R&D Pipeline Drives Continued Commercial Progress – Efficient Integration of Acquired Assets Supports Long-Term Growth Trajectory Results Highlights: – Revenue and net profit reached US$78.9 million and US$18.8…
OrbusNeich’s Joint Venture Kicks Off TricValve Clinical Trial in Mainland China
Enhances Patients’ Quality of Life with Minimally Invasive Transcatheter Therapy OrbusNeich Medical Group Holdings Limited (OrbusNeich or the HKG: 6929), a major global medical device manufacturer specializing in interventional devices…
OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share
Strategic M&A Initiatives Boost Product Portfolio and Market Penetration Reinforcing Business Pillars for Future Growth OrbusNeich Medical Group Holdings Limited (OrbusNeich or the Group; HKG: 6929), a major global medical…
OrbusNeich Kicks Off Clinical Study of Scoreflex TRIO, Completing China’s First PCI Intervention Procedure with High-Pressure, Three-wire Scoring Balloon Dilatation Catheter
OrbusNeich Medical Group Holdings Limited (OrbusNeich or the Group; HKG: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty…